Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Medical Microbiologists (US)(?)

Council Members in this Study Group: 70

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.Richard Anthony, PhD
Board member
Janus Pharmaceuticals, Inc.

Richard Anthony, PhD, is the Chief Executive Officer at Catalyst Pharma Group, Inc., California, a contract research organization providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies. He also serves as the Board Member of Janus...

1 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
DNAi - early stage excitement | 03-27-2008
Analysis of: Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic | www.pipelinereview.com
Author: GLG Expert Contributor

DNAi technology, as presented by Pronal Therapeutics provides an exciting opportunity to use this technology as a therapeutic.  PNT2258 may be an important nucleic acid in combating certain types of cancer and solid tumor.  It is an important milestone to have FDA acceptance to begin Phase...

PDE-5 class effect on Raynauds may provide evidence that SLx-2101 will work | 07-02-2007
Analysis of: Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease | www.pipelinereview.com
Author: Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.

Viagra (sildenafil) a same a PDE-5 same  class compound as SLx-2101 has shown efficacy for Raynaud's by significantly reducing the frequency and duration of Raynaud attacks and improved capillary flow velocity by 400%, according to a study led by Roland Fries, M.D and published online...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Institution*
  • Academic Medical Center/Hospital or Clinic
  • Pharmaceuticals Manufacturer
  • Contract Research Organization, Independent/Small
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Research Scientist
  • Professor
  • Director
  • Researcher
  • Assistant Professor
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T09:46:13.947